Skip to search formSkip to main contentSkip to account menu

pan-RAF Kinase Inhibitor TAK-580

Known as: MLN-2480, TAK580, MLN2480 
An orally available inhibitor of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, pan-RAF kinase… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in…
TPS2609 Background: Signaling hyperactivation secondary to MAPK pathway aberrations are common. RAF kinases play key roles in the… 
2015
2015
300 Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma
2014
2014
364 First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma
2014
2014
495 Divergent androgen regulation of UPR pathways drives prostate cancer
2014
2014
493 Preclinical pharmacokinetic (PK)/pharmacodynamic (PD)/Efficacy modeling for MLN2480, an investigational pan-RAF kinase inhibitor, in A375 and SKMEL-2 human melanoma xenografts
2014
2014
324 Clinical pharmacokinetics (PK), translational PK/pharmacodynamics (PD), and exposure–adverse events (AEs) relationship of MLN2480, an oral investigational pan-RAF kinase inhibitor
2014
2014
162 Drug–drug interaction predictions for MLN2480, an investigational pan-RAF inhibitor, based on nonclinical data
2014
2014
494 LPA6 promotes growth and tumorigenicity of hepatocellular carcinoma via activation of PIM-3 proto-oncogene kinase
2014
2014
163 Interrogation of pharmacogenes in cancer patients using targeted DNA sequencing
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)